Daily briefing: Bad supervisors bump early-career researchers out of academia

You have full access to this article via your institution. Hello Nature readers, would you like to get this Briefing in your inbox free every day? Sign up here . Pancreatic-head tumours (red, artificially coloured) have proved highly resistant to treatment, but a new drug nearly doubles the lifespan of people with this type of cancer. Credit: PNMB/Science Photo Library A drug that targets a so-called ‘undruggable’ family of proteins has nearly doubled survival in people with an advanced form of pancreatic cancer. The experimental drug, daraxonrasib, disarms all three RAS proteins, which are linked to some of the deadliest cancers. In a trial of 500 people with advanced pancreatic cancer, those who received daraxonrasib lived another 13.2 months, compared with 6.7 months for those treated with chemotherapy . Researchers hope that combining the drug with other treatments could produce longer-lasting benefits. Nature | 7 min read Reference: New England Journal of Medicine paper Bad experiences with supervisors are one of the leading reasons that early-career researchers leave academia. In a survey of more than 2,600 researchers, almost 40% of respondents said that their supervisor was disorganized and poor at communication and at least 30% reported issues concerning their supervisor’s behaviour, such as abrupt attitude changes and a lack of empathy. …